search
Back to results

Blood Pressure Management in Stroke Following Endovascular Treatment (DETECT)

Primary Purpose

Stroke, Acute, Vessels; Occlusion, Blood Pressure

Status
Active
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Labetalol
Hydralazine
Enalapril
Sponsored by
Hamilton Health Sciences Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke, Acute focused on measuring endovascular stroke treatment, successful recanalization, transcranial Doppler Ultrasound, intracranial hemorrhage

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age equal or more than 18 years.
  • Eligible for endovascular treatment (EVT) within 24 hours from symptom onset according to current clinical practice.
  • Presence of a proximal large vessel occlusion in the anterior circulation, defined as occlusion of the intracranial segment of the internal carotid artery and/or occlusion of the M1 segment or proximal M2 segment of the middle cerebral artery.
  • Successful recanalization after the end of the EVT procedure, defined as modified thrombolysis in cerebral ischemia (mTICI) score equal or more than 2b.
  • Sustained elevated systolic BP level after recanalization, defined as 2 consecutive systolic BP readings ≥ 150 mmHg (or ≥ 140 mmHg if the participant has a known history of hypertension) taken more than 5 minutes apart.
  • Ability of the patient or legal representative to provide informed consent.
  • Randomization within 60 minutes from the end of the EVT procedure.

Exclusion Criteria:

  • Presence of concomitant ipsilateral or contralateral extracranial vessel occlusion or remaining stenosis ≥80% after the end of the EVT.
  • Symptomatic intracranial hemorrhage after the end of EVT procedure.
  • Any medical condition where randomization to either standard or intensive BP lowering would not be acceptable at the discretion of the investigators and/or the treating physician.
  • Pregnancy.
  • Enrollment in another acute stroke therapeutic trial.

Sites / Locations

  • Hamilton General Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intensive Blood Pressure management

Standard Blood Pressure management

Arm Description

Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.

Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.

Outcomes

Primary Outcome Measures

Mean enrollment rate.
The predefined target is to achieve a mean enrollment rate of 2 patients per month.
Number of participants with treatment allocation change.
The predefined target is that at least 80% of the participants remain within their assigned treatment group, and not changing treatment allocation for any reason.

Secondary Outcome Measures

Number of participants with any intracranial hemorrhage.
As identified in the follow-up computed tomography scan.
Absolute difference in flow velocity measurements in transcranial Doppler.
Assessed with the adjusted mean flow velocities of the recanalized vessel on transcranial Doppler examination.
Absolute difference in the NIH Stroke Scale change at day 1.
NIH Stroke Scale ranges from 0 to 42, with higher scores indicating more severe impairment caused by a stroke.
Absolute difference in the NIH Stroke Scale change at day 2.
NIH Stroke Scale ranges from 0 to 42, with higher scores indicating more severe impairment caused by a stroke.

Full Information

First Posted
July 6, 2020
Last Updated
March 8, 2023
Sponsor
Hamilton Health Sciences Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT04484350
Brief Title
Blood Pressure Management in Stroke Following Endovascular Treatment
Acronym
DETECT
Official Title
Blood Pressure Management in Stroke Following Endovascular Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 23, 2020 (Actual)
Primary Completion Date
May 23, 2023 (Anticipated)
Study Completion Date
May 23, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hamilton Health Sciences Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of DETECT is to prove the feasibility of a multicenter phase III trial testing the hypothesis that intensive blood pressure control immediately after successful endovascular stroke thrombectomy can improve patient outcomes. Patients with stroke who have ongoing high blood pressure after successful clot retrieval will be included. Participants will be randomly placed (like flipping a coin) in one of two groups. There will be a 50% chance of each patient being placed to either group. The first group will be allowed to have a higher blood pressure range that is consistent with current recommendations. The second group will be given medications to bring their blood pressure down into a normal range. These blood pressure targets will be maintained for 48 hours. We will collect patient brain images and levels of stroke disability up to 90 days after their clot retrieval.
Detailed Description
Current guidelines from the American Heart Association/ American Stroke Association (AHA/ ASA) propose thresholds of systolic blood pressure (BP) less than 180 mm Hg and diastolic BP less than 105 mm Hg during and for the first 24 hours following endovascular treatment (EVT), which have been arbitrarily inherited from previous intravenous thrombolysis guidelines. Although there is plethora of evidence from observational cohort studies suggesting that increased BP following EVT is associated with higher likelihood of both intracranial hemorrhage and unfavorable clinical outcomes, the potential for residual confounding in these observational datasets limits their interpretation. The blooD prEssure management in sTroke following EndovasCular Treatment (DETECT) trial is a single-center, pragmatic, pilot, prospective open label, blinded end point, randomized controlled trial testing the hypothesis that intensive BP management following successful EVT is feasible. The primary objective of DETECT is to determine the feasibility of a RCT assessing the efficacy and safety of intensive BP lowering compared to standard of care in rates of hemorrhagic transformation and functional outcome following successful EVT in acute ischemic stroke patients with large vessel occlusion. We will include adult patients with acute ischemic stroke achieving successful reperfusion (TICI more or equal to 2b) of a proximal large vessel occlusion in the anterior circulation after EVT. Eligible patients will be randomized 1:1 within 60 minutes from the end of the EVT procedure to either intensive (systolic BP target <140 mmHg) or standard BP management (systolic BP target <180 mmHg) for the first 48 hours after randomization. Patients with presence of concomitant ipsilateral or contralateral extracranial vessel occlusion or remaining stenosis ≥80% after the end of the EVT, and/or patients having any medical condition where randomization to either standard or intensive BP lowering would not be acceptable at the discretion of the treating physician will be excluded from participating. The trial will be embedded within an established national EVT registry that focuses on improving quality of management of patients receiving EVT for ischemic stroke.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute, Vessels; Occlusion, Blood Pressure, Endovascular Thrombectomy, Mechanical Thrombectomy
Keywords
endovascular stroke treatment, successful recanalization, transcranial Doppler Ultrasound, intracranial hemorrhage

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intensive Blood Pressure management
Arm Type
Experimental
Arm Description
Participants assigned to the intensive blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 140 mmHg for the first 48 hours after enrollment into the study.
Arm Title
Standard Blood Pressure management
Arm Type
Active Comparator
Arm Description
Participants assigned to the standard blood pressure management arm will be treated using approved antihypertensive medications to have systolic blood pressure readings under 180 mmHg for the first 48 hours after enrollment into the study.
Intervention Type
Drug
Intervention Name(s)
Labetalol
Intervention Description
10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
Intervention Type
Drug
Intervention Name(s)
Hydralazine
Intervention Description
10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
Intervention Type
Drug
Intervention Name(s)
Enalapril
Intervention Description
1.25 - 2.5 mg IV bolus and then q6h PRN.
Primary Outcome Measure Information:
Title
Mean enrollment rate.
Description
The predefined target is to achieve a mean enrollment rate of 2 patients per month.
Time Frame
through study completion, an average of 18 months
Title
Number of participants with treatment allocation change.
Description
The predefined target is that at least 80% of the participants remain within their assigned treatment group, and not changing treatment allocation for any reason.
Time Frame
48 hours from treatment initiation
Secondary Outcome Measure Information:
Title
Number of participants with any intracranial hemorrhage.
Description
As identified in the follow-up computed tomography scan.
Time Frame
24±12 hours from treatment initiation
Title
Absolute difference in flow velocity measurements in transcranial Doppler.
Description
Assessed with the adjusted mean flow velocities of the recanalized vessel on transcranial Doppler examination.
Time Frame
0-18 hours from treatment initiation
Title
Absolute difference in the NIH Stroke Scale change at day 1.
Description
NIH Stroke Scale ranges from 0 to 42, with higher scores indicating more severe impairment caused by a stroke.
Time Frame
24±12 hours from treatment initiation
Title
Absolute difference in the NIH Stroke Scale change at day 2.
Description
NIH Stroke Scale ranges from 0 to 42, with higher scores indicating more severe impairment caused by a stroke.
Time Frame
48±12 hours from treatment initiation
Other Pre-specified Outcome Measures:
Title
Absolute difference in mean systolic blood pressure values.
Description
Difference in mean systolic blood pressure values between the two arms.
Time Frame
48 hours from treatment initiation
Title
Number of participants with symptomatic intracranial hemorrhage.
Description
According to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), National Institute of Neurological Disorders and Stroke (NINDS) and European-Australian Cooperative Acute Stroke Study 2 (ECASS 2) definitions.
Time Frame
24±12 hours from treatment initiation
Title
Number of deaths during hospitalization.
Description
All-cause in-hospital mortality.
Time Frame
Day 7 from treatment initiation or hospital discharge
Title
Number of deaths during follow-up.
Description
All-cause mortality.
Time Frame
Day 90±10 from treatment initiation
Title
Number of participants with neurological deterioration.
Description
Defined as ≥4 points decline in the National Institute of Health Stroke Scale (NIHSS) from randomization or death.
Time Frame
24 hours from treatment initiation
Title
Functional outcome during hospitalization.
Description
Ordinal shift analysis of the full range of category scores (0-6) of the modified Rankin Scale (mRS).
Time Frame
Day 7 from treatment initiation or hospital discharge
Title
Functional outcome during follow-up.
Description
Ordinal shift analysis of the full range of category scores (0-6) of the modified Rankin Scale (mRS).
Time Frame
Day 90±10 from treatment initiation
Title
Number of participants with favorable functional outcomes during hospitalization.
Description
Favorable functional outcomes defined as modified Rankin Scale (mRS) scores of 0-1 or 0-2.
Time Frame
Day 7 from treatment initiation or hospital discharge
Title
Number of participants with favorable functional outcomes during follow-up
Description
Favorable functional outcomes defined as modified Rankin Scale (mRS) scores of 0-1 or 0-2.
Time Frame
Day 90±10 from treatment initiation
Title
Absolute difference in the decline of the Alberta stroke program early CT scores.
Description
The Alberta Stroke Program Early CT Score (ASPECTS) is a 10-point (range 0-10) quantitative topographic imaging scale with higher scores indicating more favorable imaging profiles. Differences will be assessed between the baseline and repeat computed tomography scan.
Time Frame
24±12 hours from treatment initiation
Title
Absolute difference in final infarct volumes.
Description
As assessed in the magnetic resonance imaging (MRI) scan, when available.
Time Frame
Day 7 from treatment initiation
Title
Absolute difference in hospital stay.
Description
Duration of hospital length of stay in days.
Time Frame
Day 7 from treatment initiation or hospital discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age equal or more than 18 years. Eligible for endovascular treatment (EVT) within 24 hours from symptom onset according to current clinical practice. Presence of a proximal large vessel occlusion in the anterior circulation, defined as occlusion of the intracranial segment of the internal carotid artery and/or occlusion of the M1 segment or proximal M2 segment of the middle cerebral artery. Successful recanalization after the end of the EVT procedure, defined as modified thrombolysis in cerebral ischemia (mTICI) score equal or more than 2b. Sustained elevated systolic BP level after recanalization, defined as 2 consecutive systolic BP readings ≥ 150 mmHg (or ≥ 140 mmHg if the participant has a known history of hypertension) taken more than 5 minutes apart. Ability of the patient or legal representative to provide informed consent. Randomization within 60 minutes from the end of the EVT procedure. Exclusion Criteria: Presence of concomitant ipsilateral or contralateral extracranial vessel occlusion or remaining stenosis ≥80% after the end of the EVT. Symptomatic intracranial hemorrhage after the end of EVT procedure. Any medical condition where randomization to either standard or intensive BP lowering would not be acceptable at the discretion of the investigators and/or the treating physician. Pregnancy. Enrollment in another acute stroke therapeutic trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aristeidis H Katsanos, MD
Organizational Affiliation
Hamilton General Hospital, Hamilton Health Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hamilton General Hospital
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L2X2
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Blood Pressure Management in Stroke Following Endovascular Treatment

We'll reach out to this number within 24 hrs